Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19

This article describes the results of a preclinical safety and immunogenicity study of QazCovid-in®, the first COVID-19 vaccine developed in Kazakhstan, on BALB/c mice, rats, ferrets, Syrian hamsters and rhesus macaques (Macaca mulatta). The study’s safety data suggests that this immunobiological pr...

Full description

Bibliographic Details
Main Authors: Ainur Nurpeisova, Berik Khairullin, Ruslan Abitaev, Kamshat Shorayeva, Kuanish Jekebekov, Elina Kalimolda, Aslan Kerimbayev, Karligash Akylbayeva, Zhandos Abay, Balzhan Myrzakhmetova, Aziz Nakhanov, Zharkinay Absatova, Sergazy Nurabayev, Mukhit Orynbayev, Nurika Assanzhanova, Khairulla Abeuov, Lespek Kutumbetov, Markhabat Kassenov, Yergaly Abduraimov, Kunsulu Zakarya
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
covid-19
vaccine
safety
toxicity
immunogenicity
preclinical trials
Online Access:http://dx.doi.org/10.1080/21645515.2022.2087412

Internet

http://dx.doi.org/10.1080/21645515.2022.2087412

Similar Items